Asia Pacific Biosimulation Market Size & Outlook
Asia Pacific biosimulation market, 2016-2028 (US$M)
Related Markets
Asia Pacific biosimulation market highlights
- The Asia Pacific biosimulation market generated a revenue of USD 468.9 million in 2021.
- The market is expected to grow at a CAGR of 17.4% from 2022 to 2028.
- In terms of segment, software was the largest revenue generating product in 2021.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2022 to 2028.
Asia Pacific data book summary
| Market revenue in 2021 | USD 468.9 million |
| Market revenue in 2028 | USD 1,445.4 million |
| Growth rate | 17.4% (CAGR from 2021 to 2028) |
| Largest segment | Software |
| Fastest growing segment | Services |
| Historical data covered | 2016 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Software, Services |
| Key market players worldwide | Certara Inc Ordinary Shares, Dassault Systemes SE, Avantium NV, Simulations Plus Inc, Schrodinger Inc Ordinary Shares, Chemical Computing Group, Physiomics, Rosa & Co, Genedata AG, Instem, Yokogawa Electric Corp., Immunetrics |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 19.3% of the global biosimulation market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2028.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,445.4 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimulation Market Scope
Biosimulation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific biosimulation market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimulation market will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 68.8% in 2021. Horizon Databook has segmented the Asia Pacific biosimulation market based on software, services covering the revenue growth of each sub-segment from 2016 to 2028.
The Asia Pacific biosimulation market is anticipated to exhibit the fastest CAGR of 17.6% during the forecast period owing to increasing number of CROs, growing healthcare IT spending, and rapidly evolving healthcare infrastructure.
Similarly, in developed countries such as Australia, the market is expected to grow rapidly. For instance, the National Information and Communication Technology Australia (NICTA) is expected to expedite its research on data mining, networks, and embedded systems to be used in this field.
Most IT companies are making significant investments in biosimulation market. Investments from major IT players, such as IBM, Infosys, and TCS, are expected to boost the growth of this market.
Reasons to subscribe to Asia Pacific biosimulation market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific biosimulation market databook
-
Our clientele includes a mix of biosimulation market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific biosimulation market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific biosimulation market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific biosimulation market size, by country, 2016-2028 (US$M)
Asia Pacific Biosimulation Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
